Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

ADC Therapeutics (ADCT) EBT Margin (2019 - 2026)

ADC Therapeutics has reported EBT Margin over the past 8 years, most recently at 164.57% for Q1 2026.

  • Quarterly results put EBT Margin at 164.57% for Q1 2026, up 60417.0% from a year ago — trailing twelve months through Mar 2026 was 281.38% (up 16.0% YoY), and the annual figure for FY2022 was 73.68%, down 7286.0%.
  • EBT Margin reached 164.57% in Q1 2026 per ADCT's latest filing, up from 260.1% in the prior quarter.
  • Across five years, EBT Margin topped out at 0.0% in Q4 2022 and bottomed at 768.74% in Q1 2025.
  • Median EBT Margin over the past 5 years was 256.9% (2024), compared with a mean of 255.49%.
  • The largest annual shift saw EBT Margin surged 154587bps in 2022 before it plummeted -51504bps in 2025.
  • Over 5 years, EBT Margin stood at 0.0% in 2022, then crashed by -1082939463bps to 313.25% in 2023, then increased by 23bps to 242.11% in 2024, then decreased by -7bps to 260.1% in 2025, then skyrocketed by 37bps to 164.57% in 2026.
  • Business Quant data shows EBT Margin for ADCT at 164.57% in Q1 2026, 260.1% in Q3 2025, and 294.03% in Q2 2025.